|
1
|
Shima DT, Adamis AP, Ferrara N, Yeo KT,
Yeo TK, Allende R, et al: Hypoxic induction of endothelial cell
growth factors in retinal cells: identification and
characterization of vascular endothelial growth factor (VEGF) as
the mitogen. Mol Med. 1:182–193. 1995.PubMed/NCBI
|
|
2
|
Greenberger S, Boscolo E, Adini I,
Mulliken JB and Bischoff J: Corticosteroid suppression of VEGF-A in
infantile hemangioma-derived stem cells. N Engl J Med.
362:1005–1013. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xiao X, Liu J and Sheng M: Synergistic
effect of estrogen and VEGF on the proliferation of hemangioma
vascular endothelial cells. J Pediatr Surg. 39:1107–1110. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kleinman ME, Greives MR, Churgin SS,
Blechman KM, Chang EI, Ceradini DJ, et al: Hypoxia-induced
mediators of stem/progenitor cell trafficking are increased in
children with hemangioma. Arterioscler Thromb Vasc Bio.
27:2664–2670. 2007. View Article : Google Scholar
|
|
5
|
Tokuyama W, Mikami T, Masuzawa M and
Okayasu I: Autocrine and paracrine roles of VEGF/VEGFR-2 and
VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face.
Hum Pathol. 41:407–414. 2010. View Article : Google Scholar
|
|
6
|
Elmasri H, Karaaslan C, Teper Y, Ghelfi E,
Weng M, Ince TA, et al: Fatty acid binding protein 4 is a target of
VEGF and a regulator of cell proliferation in endothelial cells.
FASEB J. 23:3865–3873. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Haggstrom AN, Drolet BA, Baselga E,
Chamlin SL, Garzon MC, Horii KA, et al: Prospective study of
infantile hemangiomas: clinical characteristics predicting
complications and treatment. Pediatrics. 118:882–887. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Span PN, Grebenchtchikov N, Geurts-Moespot
J, Westphal JR, Lucassen AM and Sweep CG: EORTC Receptor and
Biomarker Study Group Report: a sandwich enzyme-linked
immunosorbent assay for vascular endothelial growth factor in blood
and tumor tissue extracts. Int J Biol Markers. 15:184–191.
2000.PubMed/NCBI
|
|
9
|
Ozawa CR, Banfi A, Glazer NL, et al:
Microenviromental VEGF concentration, not total dose, determines a
threshold between normal and aberrant angiogenesis. J Clin Invest.
113:516–527. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mulliken JB and Glowacki J: Hemangiomas
and vascular malforations in infants and children: a classification
based on endothelial characteristics. Plast Reconstr Surg.
69:412–422. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tanner JL, Dechert MP and Frieden IJ:
Growing up with a facial hemangioma: parent and child coping and
adaptation. Pediatrics. 101:446–452. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu LJ, Xiao C and Zhu X: New advances in
treatment of tumour using VEGF and its receptor. Oncology section
of foreign medicine science. 28:113–115. 2001.
|
|
13
|
Bruckner AL and Frieden IJ: Hemangiomas of
infancy. J Am Acad Dermatol. 48:477–493. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bitar MA, Moukarbel RV and Zalzal GH:
Management of congenital subglottic hemangioma: trends and success
over the past 17 years. Otolaryngol Head Neck Surg. 132:226–231.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tischer E, Mitchell R, Hartman T, Silva M,
Gospodarowicz D, Fiddes JC and Abraham JA: The human gene for
vascular endothelial growth factor. Multiple protein forms are
encoded through alternative exon splicing. J Biol Chem.
266:11947–11954. 1991.PubMed/NCBI
|
|
16
|
Ferrara N: Vascular endothelial growth
factor: basic science and clinical progress. Endocr Rev.
25:581–611. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Senger DR, Perruzzi CA, Feder J and Dvorak
HF: A highly conserved vascular permeability factor secreted by a
variety of human and rodent tumor cell lines. Cancer Res.
46:5629–5632. 1986.PubMed/NCBI
|
|
18
|
Zachary I and Gliki G: Signaling
transduction mechanisms mediating biological actions of the
vascular endothelial growth factor family. Cardiovasc Res.
49:568–581. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kirito K and Kaushansky K: Thrombopoietin
stimulates vascular endothelial cell growth factor (VEGF)
production in hematopoietic stem cells. Cell Cycle. 4:1729–1731.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Minchenko A, Bauer T, Salceda S and Caro
J: Hypoxic stimulation of vascular endothelial growth factor
expression in vitro and in vivo. Lab Invest. 71:374–379.
1994.PubMed/NCBI
|
|
21
|
Mahajan D, Miller C, Hirose K, McCullough
A and Yerian L: Incidental reduction in the size of liver
hemangioma following use of VEGF inhibitor bevacizumab. J Hepatol.
49:867–870. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Berse B, Brown LF, Van de Water L, Dvorak
HF and Senger DR: Vascular permeability factor (vascular
endothelial growth factor) gene is expressed differentially in
normal tissues, macrophages, and tumors. Mol Biol Cell. 3:211–220.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kastrup J, Jørgensen E, Rück A, Tägil K,
Glogar D, Ruzyllo W, et al; Euroinject One Group. Direct
intramyocardial plasmid vascular endothelial growth factor-A165
gene therapy in patients with stable severe angina pectoris. A
randomized double-blind placebo-controlled study: the Euroinject
One trial. J Am Coll Cardiol. 45:982–988. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Couffinhal T, Kearney M, Witzenbichler B,
Chen D, Murohara T, Losordo DW, et al: Vascular endothelial growth
factor/vascular permeability factor (VEGF/VPF) in normal and
atherosclerotic human arteries. Am J Pathol. 150:1673–1685.
1997.PubMed/NCBI
|
|
25
|
Inoue M, Itoh H, Ueda M, Naruko T, Kojima
A, Komatsu R, et al: Vascular endothelial growth factor (VEGF)
expression in human coronary atherosclerotic lesions: possible
pathophysiological significance of VEGF in progression of
atherosclerosis. Circulation. 98:2108–2116. 1998. View Article : Google Scholar : PubMed/NCBI
|
